Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma

European Journal of Haematology

Volumn 77, Issue 2, 2006, Pages 91-101

  Hentschel, N ^a   Krusch, M ^b   Kiener, P A ^c   Kolb, H J ^a,d   Salih, H R ^b   Schmetzer, H M ^a,d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c BRISTOL MYERS SQUIBB   (United States)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Acute myeloid leukemia; CD 137 ligand 4 1BB ligand; CD178 fas ligand; Non Hodgkin's lymphoma

Indexed keywords

CD137 ANTIGEN; FAS LIGAND; LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; MALE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN FUNCTION; REFERENCE VALUE; RISK ASSESSMENT;

4-1BB LIGAND; ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; BLAST CRISIS; CHILD, PRESCHOOL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FAS LIGAND PROTEIN; FEMALE; HUMANS; LEUKEMIA, CALLA-POSITIVE; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, MYELOID; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; LYMPHOMA, T-CELL; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES; SOLUBILITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTORS;

EID: 33745727598     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2006.00679.x     Document Type: Article

References (39)

1. YIN HF, LI T, LI JX. Retrospective analysis of 304 cases of malignant lymphomas in pathology: study and practise of the WHO classification on lymphoid naoplasms. Zhonghua Yi Xue Za Zhi 2003;83:1556-1560.
2. COFFEY J, HODGSON DC, GOSPODAROWICZ MK. Therapy of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003;30(Suppl. 1):S28-S36.
3. LORAND-METZE I, PEREIRA FG, COSTA FP, METZE K. Proliferation in non-Hodgkin's lymphomas and its prognostik value related to staging parameters. Cell Oncol 2004;26:63-71.
4. EVANS LS, HANCOCK BW. Non-Hodgkin lymphoma. Lancet 2003;362:139-146.
5. VARDIMAN JW, HARRIS NL, BRUNNING RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302.
6. ROTHE G, SCHMITZ G, for the Working Group on Cytometry and Image Analysis. Members of the editorial committee: Adorf D, Barlage S, Gramatzki M, Hanenberg H, Höffkes HG, Janossy G, Knüchel R, Ludwig WD, Nebe T, Nerl C, Orfao A, Serke S, Sonnen R, Tichelli A, Wörmann B. Consensus protocol for the flow cytimetric immunophenotyping of hematopoietic malignancies. Leukemia 1996;10:877-895.
7. SIEVERS EL, LARSON RA, STADTMAUER EA, STEY E, LoWENBERG B, DOMBRET H. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemiain fist relapse. J Clin Oncol 2004;22:1087-1094.
8. HAFERLACH T, SCHOCH C, LOFFLER H, et al.. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol 2003;21:256-265.
9. LOCKSLEY RM, KILLEEN N, LEONARDO MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell Press 2001;104:487-501.
10. SALIH HR, KOSOWSKI SG, HALUSKA VF, STARLING GC, Loo DT, LEE F, ARUFFO AA, TRAIL PA, KIENER PA. Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells. J Immunol 2000;165:2903-2910.
11. SALIH HR, SCHMETZER HM, BURKE C, STARLING GC, DUNN R, PELKA-FLEISCHER R, NÜSSLER V, KIENER PA. Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies. J Immunol 2001;167:4059-4066.
12. PALMA C, BINASHI M, BIGIONI M, MAGGI CA, GOSO C. CD137 and CD137 ligand constitutively coexpressed on human T and B leukemia cells signal proliferation and survival. Int J Cancer 2004;108:390-398.
13. DEBENEDETTE MA, CHU NR, POLLOK KE, HURTADO J, WADE WF, KWON BS, WATTS TH. Role of 4-1BB ligand in costimulation of T lymphozyte growth and its upregulation on M12 B lymphomas by cAMP. J Exp Med 1999;181:985-992.
14. MULLAUER L, MOSBERGER I, CHOTT A. Fas ligand expression on nodal non-Hodgkin's lymphoma. Mod Pathol 1998;11:369-375.
15. IMAI C, IWAMOTO S, CAMPANA D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005;106:367-383.
16. BLAZAR BR, KWON BS, PANOSKAHSIS-MORTARI A, KWAK KB, PESCHON JJ, TAYLOR PA. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in albogeneic bone marrow transplant recipients. Immunol 2001;166:3174-3183.
17. SICA G, CHEN L. Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy. Arch Immunol Ther Exp (Warsz) 1999;47:275-279.
18. CHEUK ATC, MUFTI GJ, GUINN B. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther 2004;11:215-226.
19. MITTLER RS, FOELL J, MCCAUSLAND M, STRAHOTIN S, NIU L, BAPAT A, EWES LB. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer. Immunol Res 2004;29:197-208.
20. TRAUTH BC, KLAS C, PETERS AM, MATZKU S, MOLLER P, FALK W, DEBATIN KM, KRAMMER PH. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-305.
21. IGNEY FH, KRAMMER PH. Tumor counterattack: fact or fiction? Cancer Immunol Immunother 2005;54:1127-1136.
22. DAI Z, REEL M, DENG S, DIGGS L, LARSEN CP, ROTHSTEIN DM, LAKKIS FG. Impaired recall of CD8 memory T cells in immunologically privileged tissue. J Immunol 2005;174:1165-1170.
23. GERSUK GM, BECKHAM C, LOKEN MR, KIENER P, ANDERSON JE, FARRAND A, TROUTT AB, LEDBETTER JA, DEEG HJ. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998;103:176-188.
24. MATIVI BY, MUNDLE S, ALI A, et al. Fas/CD178 system could be one of the mediators of excessive apoptosis in myelodysplastic syndromes. Blood 1997;90(Suppl. 1):202.
25. GUPTA P, NIEHANS GA, LEROY SC, GUPTA K, MORRISON VA, SCHULTZ C, KNAPP DJ, KRATZKE RA. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival. Leukemia 1999;13:44-53.
26. CLAESSENS YE, BOUSCARY D, DUPONT JM, PICARD F, MELLE J, GISSELBRECHT S, LACOMBE C, DREYFUS F, MAYEUX P, FONTENAY-ROUPIE M. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 2002;99:1594-1601.
27. SALIH HR, STARLING GC, BRANDL SF, PELKA-FLEISCHER R, HAFERLACH T, HIDDEMANN W, KIENER PA, NUESSLER V. Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo-1) and Fas ligand (CD178) expression. Br J Haeamtol 2002;117:76-85.
28. BUZYN A, PETIT F, OSTANKOVITCH M, FIGUEIREDO S, VARET B, GUILLET JG, AMEISEN JC, ESTAQUIER J. Membrane-bound Fas (Apo-1/CD95) ligand on leukamic cells: a mechanism of tumor immune escape in leukemia patients. Blood 1999;117:76-85.
29. JUNG HW, CHOI JI, KWON BS. Serum concentrations of solubile 4-1BB and 4-1BB ligand correlated with the disease severityin rheumatoid arthritis. Exp Mol Med 2004;36:13-22.
30. KATO K, SANTANA-SAHAGUN E, RASSENTI LZ, WEISMAN MH, TAMURA N, KOBAYASHI S, HASHIMOTO H, KIPPS TJ. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 1999;104:947-955.
31. JODO S, KOBAYASHI S, KAYAGAKI N, et al.. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol 1997;107:89-95.
32. MOLICA S, VITELLI G, LEVATO D, CRISPINO G, DELL'OLIO M, DATTILO A, MATERA R, GANDOLFO GM, MUSTO P. CD27 in B-cell chronic lymphocytic leukemia. Cellular expression, serum release and correlation with other soluble molecules belonging to nerve growth factor receptors (NGFr) superfamily. Haematologica 1998;83:398-402.
33. SCHNEIDER P, HOLLER N, BODMER JL, HAHNE M, FREI K, FONTANA A, TSCHOPP J. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of the proapoptotic activity and loss of liver activity. J Exp Med 1998;187:1205-1213.
34. TANAKA M, ITAI T, ADACHI M, NAGATA S. Downregulation of Fas ligand by shedding. Nat Med 1998;4:31-36.
35. SALIH HR, STARLING GC, KNAUFF M, DAVIS PM, PITTS WJ, ARUFFO A, KIENER PA. Retinoic acid and vitamin E modulate expression and release of CD178 in carcinoma cells: consequences for induction of apoptosis in CD95 sensitive cells. Exp Cell Res 2001;270:248-258.
36. SALIH HR, NUESSLER V, CLAUDIO D, STARLING GC, PETER A. Serum levels of CD137 ligand and CD178 are prognostic factors for progression of myelodysplastic syndrome. Leuk Lymphoma 2004;45:301-308.
37. MAZUMDAR M, GLASSMAN JR. Categorizing a prognostic variable: review of methods, code for easy implementation and application to decision-making about cancer treatments. Stat Med 2000;19:113-132.
38. MICHEL J, PAULY S, LANGSTEIN P, KRAMMER PH, SCHWARZ H. CD137-induced apoptosis is independent of CD95. Immunology 1999;98:42-46.
39. LANGSTEIN J, MICHEL J, SCHWARZ H. CD137 induces proliferation and endomitosis in monocytes. Blood 1999; 94:3161-3168.